Insulin Aspart (novolog) Injectable Generics - Manufacturers & Suppliers
Novolog, Fiasp(US &EU)
| Product/Composition:- | Insulin Aspart (Novolog) injectable |
|---|---|
| Strength:- | U-100, U-200 |
| Form:- | Vials/pens |
| Reference Brands:- | Novolog, Fiasp(US &EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Insulin Aspart (Novolog) is a rapid-acting insulin that mimics natural insulin release after meals. It quickly lowers blood sugar levels, providing flexible timing for meals. Its benefits include rapid onset, precise glucose control, reduced post-meal hyperglycemia, and improved convenience for insulin therapy in both type 1 and type 2 diabetes management.
Insulin Aspart (Novolog) is a rapid-acting insulin approved in the EU and US for controlling blood glucose during meals. In the EU, Novo Nordisk’s Novolog and Fiasp are regulated by the EMA, with dossiers demonstrating safety, efficacy, and high manufacturing standards. In the US, the FDA has approved NovoLog and Fiasp based on comprehensive clinical data and biosimilarity studies, ensuring quality and consistency. Both regions require detailed regulatory dossiers and ongoing pharmacovigilance for safety monitoring. For expert assistance with regulatory dossiers and compliance, visit PharmaTradz, your trusted partner in pharmaceutical regulatory services.